The tweet was deleted by the author.
But we saved everything 🙂.
Rigel Pharmaceuticals announced that its partner Kissei has submitted a New Drug Application (NDA) in Japan for olutasidenib, aimed at treating relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation.
The NDA submission marks a significant milestone in expanding olutasidenib access for Japanese patients with limited treatment options. Analysts are watching the regulatory review closely for potential commercial impact should approval be granted.
View post on X Loading...
Rigel Pharmaceuticals recently signed a global license agreement to develop, manufacture and commercialize VEPPANU (vepdegestrant). The company is also scheduled to release its first-quarter 2026 financial results and provide a business update on May 5 2026. These developments come as Rigel continues to expand its pipeline and commercial activities.